New treatment for cervical cancer resistant to chemotherapy and radiation
Novel Antimicrobial Approach to Treat Chemoradiation Resistant Cervical Cancer by Selectively Inhibiting Lactobacillus iners
['FUNDING_SBIR_1'] · OSEL, INC. · NIH-11062829
This study is exploring a new way to help women with cervical cancer that doesn't respond to regular treatments by using a special substance to target harmful bacteria, which could make existing treatments work better.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OSEL, INC. (nih funded) |
| Locations | 1 site (MOUNTAIN VIEW, UNITED STATES) |
| Trial ID | NIH-11062829 on ClinicalTrials.gov |
What this research studies
This research investigates a novel antimicrobial approach to treat cervical cancer that does not respond to traditional chemotherapy and radiation. It focuses on a specific bacteriocin, GasK7B, which selectively inhibits Lactobacillus iners, a bacteria that can hinder treatment effectiveness. The study will synthesize this bacteriocin and evaluate its ability to enhance the effectiveness of existing cancer treatments in laboratory models. By targeting the harmful bacteria while preserving beneficial ones, this approach aims to improve outcomes for women with cervical cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with cervical cancer who are experiencing resistance to chemoradiation treatments.
Not a fit: Patients with cervical cancer who are not resistant to chemoradiation or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that enhances the effectiveness of chemotherapy and radiation for cervical cancer patients.
How similar studies have performed: While this approach is novel, previous research has shown promise in using bacteriocins for targeted antimicrobial therapy, suggesting potential for success.
Where this research is happening
MOUNTAIN VIEW, UNITED STATES
- OSEL, INC. — MOUNTAIN VIEW, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LAGENAUR, LAUREL A. — OSEL, INC.
- Study coordinator: LAGENAUR, LAUREL A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.